Cargando…
A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy
Lung cancer is the leading cause of cancer-related mortality worldwide. The treatment of advanced lung cancer is improving with the development of new treatments like immune checkpoint inhibitors (ICIs) and various molecular targeted agents, which have extended overall survival (OS). However, comple...
Autores principales: | Vilas-Boas, Isabel, Moreira, Inês, Rodrigues, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840782/ https://www.ncbi.nlm.nih.gov/pubmed/36654654 http://dx.doi.org/10.7759/cureus.32585 |
Ejemplares similares
-
Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023) -
Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021) -
Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
por: Shannon, Alexander H., et al.
Publicado: (2023) -
Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
por: Jungles, Kassidy M., et al.
Publicado: (2022)